Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (10707)	2/28/2004 1:52:21 PM
From: zeta1961	Respond to of 52153

I'm relieved too! Although not part of SEPR, following your thread here I was feeling vicariously involved and hence, nervous... Congrats all... Regards, Zeta

To: jayhawk969 who wrote (10707)	2/29/2004 12:22:56 PM
From: quidditch	Read Replies (3) \| Respond to of 52153

SEPR result: This is not exactly a new thought, but it struck home while thinking about the approvable letter and what I would do with my modest SEPR holdings. As much as the FDA decision regarding Estorra in and of itself is a milestone event--to have another marketed product (assuming all goes well with the re-submission), what it also does is to reduce by a significant degree the financial risk of holding SEPR and improve its valuation characteristics. That is, in reducing that degree of risk of insufficient funding, it improves the odds that development of other products in the pipe can be moved forward, in a diligent, informed and professional manner, to logical endpoints, whether those endpoints result in the filing of NDAs or not. Thus, beyond the approvable of Estorra in and of itself, I believe that Sepracor becomes a more attractive holding because of better odds on the rest of the products in development. Put differently, I think a case can be made that, beyond a discounted cash flow or multiple of revenues analysis attributable to a likely Estorra product on the market, the value of the rest of the pipe has increased. Depending on price action over the near term, I may increase my SEPR exposure with leaps. This is, of course, an admission that, when SEPR was in single digits, I saw only doom and not opportunity. (:-( quid